John Aballi Buys 24,305 Shares of Exagen Inc. (NASDAQ:XGN) Stock

Exagen Inc. (NASDAQ:XGN) CEO John Aballi purchased 24,305 shares of the company’s stock in a transaction dated Thursday, November 14th. The shares were acquired at an average cost of $2.81 per share, with a total value of $68,297.05. Following the purchase, the chief executive officer now directly owns 689,799 shares of the company’s stock, valued at approximately $1,938,335.19. The trade was a 3.65 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Exagen Price Performance

Exagen stock opened at $3.00 on Tuesday. The firm has a market cap of $52.92 million, a P/E ratio of -3.19 and a beta of 1.35. The stock’s 50 day moving average is $2.82 and its 200 day moving average is $2.41. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. Exagen Inc. has a one year low of $1.30 and a one year high of $3.71.

Exagen (NASDAQ:XGN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The firm had revenue of $12.51 million for the quarter, compared to the consensus estimate of $13.55 million. During the same quarter in the previous year, the company earned ($0.31) EPS. As a group, research analysts expect that Exagen Inc. will post -0.87 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, William Blair restated an “outperform” rating on shares of Exagen in a report on Wednesday, November 13th.

Institutional Trading of Exagen

A number of institutional investors have recently bought and sold shares of XGN. Renaissance Technologies LLC increased its holdings in Exagen by 93.3% in the second quarter. Renaissance Technologies LLC now owns 94,234 shares of the company’s stock worth $172,000 after purchasing an additional 45,476 shares in the last quarter. Creative Planning bought a new position in shares of Exagen during the 3rd quarter worth approximately $110,000. Palumbo Wealth Management LLC grew its position in shares of Exagen by 14.5% during the 3rd quarter. Palumbo Wealth Management LLC now owns 76,364 shares of the company’s stock worth $236,000 after buying an additional 9,695 shares during the period. Verus Capital Partners LLC bought a new stake in shares of Exagen in the 3rd quarter valued at $39,000. Finally, Stonepine Capital Management LLC lifted its position in shares of Exagen by 49.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 534,398 shares of the company’s stock valued at $1,651,000 after acquiring an additional 175,701 shares during the period. Institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).